Kallya (Levonorgestrel)

Levonorgestrel acts as a synthetic progestin that binds to progesterone receptors, suppressing the luteinizing hormone surge needed for ovulation. By preventing the release of an egg and altering the uterine lining, it lowers the chance of fertilization and implantation when used promptly after intercourse.

The exact dosing regimen for Kallya is determined by the prescribing healthcare professional. In most emergency‑contraception protocols, a single oral dose is administered, but the prescriber will specify the appropriate amount and timing based on individual circumstances.

Kallya is not intended for use during an established pregnancy; a pregnancy test should be negative before taking the product. Limited data suggest that levonorgestrel exposure through breastfeeding is minimal, but women should discuss any concerns with their healthcare provider.

To order Kallya, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Kallya (levonorgestrel) is a progestin‑based emergency contraceptive taken within 72 hours of intercourse, offering efficacy that declines with time. Alternatives such as ulipristal acetate may remain effective up to 120 hours and can be more potent in later windows, but both classes share similar safety profiles.

Kallya should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Kallya is taken orally as a single tablet. The tablet should be swallowed whole with a glass of water as soon as possible after unprotected intercourse, ideally within the first 72 hours for maximum effectiveness.

Serious but rare risks include severe allergic reactions (anaphylaxis), blood‑clotting events such as deep‑vein thrombosis, and ectopic pregnancy if fertilization occurs despite treatment. Any signs of severe abdominal pain, chest discomfort, rash or swelling should prompt immediate medical attention.

Kallya should be avoided by individuals with known hypersensitivity to levonorgestrel or any tablet excipients, women who are already pregnant, and those with active liver disease or a history of thromboembolic disorders unless a healthcare professional determines that benefits outweigh risks.